True, I more mean that it is at least headin in the right direction and selling seems to be exhausted for the time being anyways. Let's hope for that material revenue increase as promised.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come